0
Obstructive Lung Diseases |

Spirometry Interpretation and the Potential Risk of Misdiagnosis

Stephen Doyle, DO; Heath Latham, MD
Author and Funding Information

University of Kansas, Kansas City, MO


Chest. 2015;148(4_MeetingAbstracts):706A. doi:10.1378/chest.2275124
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Posters III

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: COPD is the 3rd leading cause of death in the United States and carries significant morbidity. The Global Initiative for Chronic Obstructive Lung disease (GOLD) was developed to help guide treatment for this disease. The 2013 GOLD update recommends pulmonary function tests (PFTs) be obtained in order to accurately diagnosis COPD. In addition, GOLD guidelines recommend annual PFTs to track stability and guide therapy. Implementation of GOLD guidelines has been shown to reduce exacerbations, improve lung function, and quality of life markers in patients with COPD. This study investigated the use of spirometry to confirm the diagnosis of COPD and the appropriateness of therapy in those with the clinical diagnosis of COPD.

METHODS: After IRB approval, a retrospective chart review was performed on 136 patients identified based on visit diagnosis codes related to COPD in an Internal Medicine resident clinic at an academic medical center between September 2013 and August 2014. Measures included documentation of initial PFTs, PFTs performed in the prior year, FEV1/FVC ratio, FEV1, and medications prescribed. Data was organized and analyzed by REDCap software.

RESULTS: Results showed 30% of patients never underwent spirometry to confirm a diagnosis of COPD, yet still were labelled with the diagnosis of COPD. Seventy percent of patients had documented PFTs, and 62% had PFTs in the past calendar year. Thirty six percent of patients had an FEV1/FVC ratio greater than 70% and by spirometric definition do not meet criteria for COPD. In addition, 54% of those inappropriately diagnosed received oral steroids for an exacerbation. There appeared to be a bias against smokers as 79% of those with a normal ratio received treatment with oral steroids.

CONCLUSIONS: In our study, the percent of patients with documented spirometry was better than recent trials showing only 33% to 50% of people with COPD had spirometry to confirm the diagnosis. Similar to recent studies, we found a significant portion of patients being labelled with COPD without supporting spirometry and unfortunately receiving therapy for a disease process they did not have. To our knowledge, this is the first study investigating the inappropriate use of systemic steroids in those misdiagnosed with COPD.

CLINICAL IMPLICATIONS: Systemic steroids have many well documented adverse effects. By not performing spirometry prior to treatment, patients can be subjected to these potentially harmful effects.

DISCLOSURE: The following authors have nothing to disclose: Stephen Doyle, Heath Latham

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543